ABSTRACT Introduction Major Depressive Disorder (MDD) is a mental health issue that
significantly affects patients' quality of life and functioning. Despite available treatments …

Introduction Vortioxetine is a multimodal-acting antidepressant that provides improvements
on cognitive function aside from antidepressants and anxiolytic effects. Vortioxetine has …

Introduction: Vortioxetine is a structurally novel medication that has recently been approved
for treatment of major depressive disorder (MDD). This medication is a serotonin reuptake …

Background Depression is a highly heterogeneous disorder, often resulting in suboptimal
response and remission rates. This underscores the need for more nuanced clinical …

Introduction: Vortioxetine is a novel antidepressant drug approved for the treatment of major
depressive disorder (MDD) in adults. It is formulated into tablets and has a dose range of 5 …

BackgroundVortioxetine has demonstrated dose-dependent efficacy in patients with major
depressive disorder (MDD), with the greatest effect observed with vortioxetine 20 mg/day …

Introduction Major depressive disorder (MDD) is a highly prevalent and burdensome
condition. This study aims to evaluate the effectiveness, tolerability, and safety of vortioxetine …

Vortioxetine (Brintellix®) is a serotonin (5-HT) transporter inhibitor that also acts on several 5-
HT receptors, such as the 5-HT 3 and 5-HT 1A receptors. It is approved in the US and the EU …

Introduction: Vortioxetine is a pharmacodynamically novel antidepressant that exerts effects
on various neurotransmitters including serotonin, noradrenaline, dopamine, glutamate …

Background Analysis of efficacy and tolerability of vortioxetine 20 mg/day, and optimal timing
of dose adjustment, in patients with major depressive disorder (MDD). Methods Pooled …